Page 34 - Sun Pharma

Sun Pharma gains 4% as Dadra plant gets EIR from USFDA

The stock was up 4% to Rs 549 on the BSE in early morning trade in otherwise subdued market.

US FDA clears Sun Pharma's Dadra plant

Dadra is Sun Pharma's second-largest plant in India, and had received 11 adverse observations in a US FDA inspection in April

Sun Pharmaceutical gets USFDA inspection report for Dadra facility

The Mumbai based pharma major however did not share the details of the EIR

Sun Pharmaceutical, Dr Reddy's line up new drugs amid price war

Arm themselves with speciality and complex drugs facing less competition

Speciality segment a key growth driver: Sun Pharma

The company's speciality initiatives target the global market with the US being one of the important markets, Shanghvi said

Pharma shares extend gain; Sun Pharma, Divi's Lab up over 10% in three days

In past three trading sessions, Nifty Pharma index surged 6%, while S&P BSE Healthcare gain 5% against 1% rise in the benchmark indices.

More pressure ahead for Sun Pharma stock

Significant price erosion in the US market and lack of triggers, product pipeline are key worries

Sun Pharma expects FY18 revenues to decline due to pricing pressure in US

Firm plans to spend up to 10% of its revenues on R&D activities

Sun Pharma stares at sharp earnings downgrades

A muted revenue outlook and higher costs will keep margins and earnings under pressure in FY18

Sun Pharma slips to Rs 424 cr Q1 loss on weak sales, anti-trust settlement

An one-off Rs 950 crore payment to settle an anti trust litigation coupled with weak performance in core India and US markets resulted in Sun Pharmaceutical Industries posting Rs 424 crore loss in first quarter FY 2018. In same period last year the company had posted a profit of Rs 2037 crore. Revenue dipped 23 per cent to Rs 6167 crore owing to continued pricing pressure in the US, regulatory challenges and GST-led de stocking in the domestic market. Domestic sales declined 5 per cent while US market revenue was down 42 per cent. The company's US subsidiary has seen 30 per cent decline in sales on a year on year basis. Also the first quarter sales in last fiscal had a high base impact owing to the as the six months exclusivity in sale of anti-leukemia drug Gleevec. Overall pricing pressure also impacted the growth. Profit before tax and exceptional items fell 70 per cent to Rs 791 crore. A Rs 950 crore outgo to settle a litigation in the US dragged the company to loss.Sun Pharma ...

Sun Pharma, 10 others settle insider trading case with Sebi

Sebi's High Powered Advisory Committee recommended the case for settlement on the payment of Rs 18 L

Sun Pharma posts net loss of Rs 425 cr in Q1 on one-off charge

US sales drop 42%; Rs 950-cr charge related to settlement of antitrust case in US

39 stocks from BSE 500 index hit 52-week lows

Tata Motors, Sun Pharma, Dr Reddy's Lab, Coal India and Amara Raja Batteries hit 52-week lows

Sun Pharma's stock dips before Q1 results

Sun Pharmaceutical Industries hit a four-year low of Rs 451 a share on the BSE exchange, a day before the largest medicine exporter is to announce its quarterly results. The stock had fallen five per cent on Wednesday to Rs 474.7, after a 31 per cent drop in sales for US subsidiary Taro. The company had cited a "difficult generic pricing environment" for the downfall.This has mean a nearly 20 per cent drop in the share over 16 trading sessions since the recent high of Rs 588 on July 19. A Bloomberg poll average of 18 analysts says the company is expected to report a 42 per cent decline in net profit for the quarter ending June, due to shrinking margin from the US business. Sun Pharma is also facing a challenge in its earnings. Its unit at Halol in Gujarat continues to be under the US sector regulator, the FDA's watch, hitting sales and profit in the biggest international market. The facility, catering to the US market, first got a warning letter from the FDA in 2015. Even after ...

Sun Pharma hits 52-week low on Taro's weak June quarter results

The stock slipped 5% to Rs 475, also its 52-week low on BSE in early morning trade.

Sun Pharma inks $55.5mn deal with Samsung BioLogics for anti-psoriasis drug

The agreement was signed at Samsung BioLogics' headquarter in Incheon, South Korea

Sun Pharma to develop chikungunya, zika drugs

Sun Pharmaceutical Industries has tied up with Pune-based National Institute of Virology to develop new drugs to treat chickungunya, dengue and zika. The partnership is a part of company's plans to develop drugs which cater to unmet needs of patients. Currently there are no vaccines or specific drugs to treat them and thus pose a health concern globally.Under the agreement NIV will conduct the tests on biological, chemical and phytopharmaceutical (plant based) molecules developed by the company against the viruses." We will work with NIV on pre-clinical studies and based on the results we will conduct clinical trials," said Dr Altaf Lal, senior adviser (global health and innovation), Sun Pharma.Sun Pharma did not disclose project funding and commercial development details.The tie up is also in sync with government's Make in India plan, the company said. Sun Pharma's agreement with NIV follows its MoU with Indian Council for Medical Research for conducting joint scientific research ...

Sun Pharma's extra discount to tide over GST wave

Sop for stockists to ensure easy availability of medicines

Sun Pharma's niche drug ramp-up key to growth

Despite the Zetia launch, FY18 could be subdued given pricing pressures

Sun Pharma wants to rise on niche route

Lost 50% market value in 2 years due to competition